Deals & IPOs

Astromech acquires Form Bio in $230 million all-stock deal

Astromech’s $230 million all-stock acquisition of Form Bio joins evolutionary modeling with gene therapy design, gives Andrew Busey a technology role, and adds tools used by Eli Lilly.

By Daniel Okafor

3 min read

Astromech Acquires Form Bio In $230 Million All-Stock Deal
Astromech Acquires Form Bio In $230 Million All-Stock DealMahmoud-Ahmed / pixabay

What's News

  • Astromech acquired Form Bio in an all-stock transaction valued at $230 million.
  • Form Bio co-founder Andrew Busey became Astromech’s chief AI officer and head of technology.
  • Form Bio reported that promoter redesign raised full-genome content from 13% to 59% in less than 30 days.
  • Coding-sequence optimization raised full-genome content from about 2% to about 45% while maintaining baseline expression.
  • Form Bio launched in 2022 and raised more than $40 million; Astromech raised more than $60 million.

By Daniel Okafor

Astromech acquired Form Bio in an all-stock transaction valued at $230 million. The deal combines predictive evolution models with software for designing and manufacturing genetic medicines.

What does the $230 million deal combine?

Astromech said the acquisition adds Form Bio’s employees, intellectual property, selected contracts and other assets. Form Bio co-founder and former CEO Andrew Busey now leads technology at Astromech. His titles are chief AI officer and head of technology. Both companies originated within the Colossal Biosciences ecosystem.

Astromech develops predictive models from genomic and functional data collected across species and evolutionary periods. It uses deep learning and Bayesian reconstruction for the work. The models study ancestral sequences, regulatory states, biological functions and vulnerabilities.

Astromech says DNA preserved across millions of years can provide evidence about biological functions. Those functions may be important to living systems. This historical evidence supplies the evolutionary layer for the combined operation.

Form Bio develops foundation models and software for genomics. Its tools also cover gene-therapy vector design, manufacturing analysis and genomic quality assessment. Its systems support the next step: constructing genetic medicines that researchers can manufacture and test.

In practical terms, Astromech supplies the evolutionary pattern-detection layer, while Form Bio provides the workflow for designing, manufacturing and testing genetic constructs within research programs. Astromech said the combination should help researchers move from identifying evolutionary patterns to creating manufacturable genetic constructs.

Astromech and Form Bio believe designers can address unwanted components at the design stage. That approach could reduce downstream purification requirements.

How does Form Bio support genetic medicine programs?

Form Bio’s capabilities support programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences. Coave’s Dr. Adrien Savy, Director of Discovery Science, said: “Form Bio’s AI-driven design platform is helping us rapidly evaluate and prioritize gene therapy constructs across multiple programs.”

Form Bio said promoter redesign in work with Cure Rare Disease involving Duchenne muscular dystrophy increased full-genome content from 13% to 59% in less than 30 days. The program has moved into animal studies.

Form Bio also reported that coding-sequence optimization increased full-genome content from approximately 2% to about 45% in another program. The result maintained baseline expression.

Form Bio said the examples were program-specific. They do not establish clinical safety or effectiveness.

Andrew Busey, Astromech’s chief AI officer and head of technology, said:

Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics.

Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines.

Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make.

Busey’s account describes a deliberate shift in Form Bio’s role. The company moved from analyzing biological data toward helping design genetic medicines. The acquisition places those design tools alongside Astromech’s evolutionary modeling.

What happens next?

Form Bio launched in 2022 and raised more than $40 million before the acquisition. Astromech has raised more than $60 million. The combined company plans to pursue applications in human therapeutics, genome engineering and animal health.

The immediate test is whether the two technical layers can shorten the path from biological evidence to manufacturable gene therapy constructs. Form Bio’s program data show faster content gains inside selected projects. Form Bio cautions that those examples do not establish clinical safety or effectiveness.

The next test will come through the Duchenne program’s animal studies and the combined company’s planned work in human therapeutics, genome engineering and animal health. Those steps will show whether Astromech can turn an all-stock acquisition into a repeatable genetic-medicine development platform.

Source: pulse2.com

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.

2,360 articles

Related articles

« Previous articleNext article »